The ULTIMATE trial demonstrated that intravascular ultrasound-guided drug-eluting stent implantation resulted in better clinical results than angiography-guided implantation.^[1] The IVUS-XPL randomized clinical trial compared intravascular ultrasound-guided versus angiography-guided everolimus-eluting stent implantation and found improved outcomes with imaging guidance.^[8] The read here is that switching to intravascular ultrasound guidance for stent placement offers a measurable advantage in clinical outcomes for patients requiring intervention. Other recent research highlights diverse clinical advances. A 2018 clinical trial conducted in Spain found that people with high cardiovascular risk who followed a Mediterranean diet with extra virgin olive oil reduced their risk of heart attack, stroke, and cardiovascular death by 30%.^[2] In oncology, a personalized mRNA vaccine combined with immunotherapy reduced the risk of melanoma recurrence by 50% in a Phase III clinical trial announced in August 2026.^[3] Moderna and Merck successfully completed Phase 3 clinical trials for their personalized mRNA cancer vaccine, Intismeran Autogene.^[7] Researchers conducted a clinical trial involving 16 patients with severe neurological and muscle autoimmune disorders who were resistant to standard treatments.^[4] The FDA clearance allows Acepodia to begin a Phase I clinical trial for ACE723 in patients with unresectable or metastatic hepatocellular carcinoma (HCC).^[5] A clinical trial involving 53 patients with normal-tension glaucoma demonstrated that Vitamin B3 significantly improved retinal cell activity compared to a placebo.^[6]